Last reviewed · How we verify
Aminohippurate (AMINOHIPPURIC ACID)
Aminohippurate, also known as Aminohippuric Acid, is a small molecule drug developed by Merck that targets the solute carrier family 22 member 6. It is an aminohippuric acid drug class and was FDA approved in 1944. The exact indications for Aminohippurate are not specified, but it is likely used to treat conditions related to its mechanism of action. As Merck is the current owner, the commercial status of Aminohippurate is likely patented, but further information is needed to confirm. Key safety considerations are not well-documented.
At a glance
| Generic name | AMINOHIPPURIC ACID |
|---|---|
| Sponsor | Merck & Co. |
| Drug class | aminohippuric acid |
| Target | Solute carrier family 22 member 6, Solute carrier family 22 member 6 |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1944 |
Approved indications
Common side effects
Key clinical trials
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 (PHASE4)
- Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes (PHASE1,PHASE2)
- Caveolin-1 and Vascular Dysfunction (PHASE1)
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2 (PHASE4)
- Renal Mechanism of SGLT2 Inhibition (PHASE2)
- MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes (PHASE1)
- Effect of Acute Hypoxia on Renal Hemodynamic in Healthy Volunteers, Patients With Diabetes and Patients With Diabetes and Kidney Disease (NA)
- Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aminohippurate CI brief — competitive landscape report
- Aminohippurate updates RSS · CI watch RSS
- Merck & Co. portfolio CI